Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Skin lightening preparations and the hydroquinone controversy.

Draelos ZD.

Dermatol Ther. 2007 Sep-Oct;20(5):308-13. Review.

PMID:
18045355
2.

Topical treatments for melasma and postinflammatory hyperpigmentation.

Lynde CB, Kraft JN, Lynde CW.

Skin Therapy Lett. 2006 Nov;11(9):1-6. Review.

3.

Natural ingredients for darker skin types: growing options for hyperpigmentation.

Alexis AF, Blackcloud P.

J Drugs Dermatol. 2013 Sep;12(9 Suppl):s123-7.

PMID:
24002160
4.

Topical agents used in the management of hyperpigmentation.

Halder RM, Richards GM.

Skin Therapy Lett. 2004 Jun-Jul;9(6):1-3. Review.

5.

Efficacy of hydroquinone-free skin-lightening cream for photoaging.

Dreher F, Draelos ZD, Gold MH, Goldman MP, Fabi SG, Puissegur Lupo ML.

J Cosmet Dermatol. 2013 Mar;12(1):12-7. doi: 10.1111/jocd.12025.

PMID:
23438137
6.

Treatment of hyperpigmentation.

Rossi AM, Perez MI.

Facial Plast Surg Clin North Am. 2011 May;19(2):313-24. doi: 10.1016/j.fsc.2011.05.010.

PMID:
21763992
7.
8.

Management of hyperpigmentation in darker racial ethnic groups.

Grimes PE.

Semin Cutan Med Surg. 2009 Jun;28(2):77-85. doi: 10.1016/j.sder.2009.04.001. Review.

PMID:
19608057
9.

Evaluation of a kojic acid, emblica extract, and glycolic acid formulation compared with hydroquinone 4% for skin lightening.

Draelos ZD, Yatskayer M, Bhushan P, Pillai S, Oresajo C.

Cutis. 2010 Sep;86(3):153-8.

PMID:
21049734
10.

Retinoids and azelaic acid to treat acne and hyperpigmentation in skin of color.

Woolery-Lloyd HC, Keri J, Doig S.

J Drugs Dermatol. 2013 Apr;12(4):434-7. Review.

PMID:
23652891
11.

4-n-butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation.

Kolbe L, Mann T, Gerwat W, Batzer J, Ahlheit S, Scherner C, Wenck H, Stäb F.

J Eur Acad Dermatol Venereol. 2013 Jan;27 Suppl 1:19-23. doi: 10.1111/jdv.12051.

PMID:
23205541
12.

Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.

Makino ET, Mehta RC, Garruto J, Gotz V, Sigler ML, Herndon JH.

J Drugs Dermatol. 2013 Mar;12(3):s21-6.

PMID:
23545929
13.

Efficacy and safety of a new triple-combination agent for the treatment of facial melasma.

Taylor SC, Torok H, Jones T, Lowe N, Rich P, Tschen E, Menter A, Baumann L, Wieder JJ, Jarratt MM, Pariser D, Martin D, Weiss J, Shavin J, Ramirez N.

Cutis. 2003 Jul;72(1):67-72.

PMID:
12889718
14.

Successful treatment of hydroquinone-resistant melasma using topical methimazole.

Malek J, Chedraoui A, Nikolic D, Barouti N, Ghosn S, Abbas O.

Dermatol Ther. 2013 Jan-Feb;26(1):69-72. doi: 10.1111/j.1529-8019.2012.01540.x.

PMID:
23384022
15.
16.

New and experimental treatments of cloasma and other hypermelanoses.

Picardo M, Carrera M.

Dermatol Clin. 2007 Jul;25(3):353-62, ix. Review.

PMID:
17662901
18.
19.
20.

Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.

Makino ET, Herndon JH, Sigler ML, Gotz V, Garruto J, Mehta RC.

J Drugs Dermatol. 2012 Dec;11(12):1478-82.

PMID:
23377519

Supplemental Content

Support Center